Medical Equipment

Cancer Diagnostics Market Expected To Reach $44.69 Billion By 2030

April 10, 2026April 10, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Cancer Diagnostics Market Projected To Reach By 2030?

The cancer diagnostics market has seen substantial expansion in recent years. It is anticipated to expand from $25.5 billion in 2025 to $28.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical growth can be linked to factors such as a rise in global cancer prevalence, increased investments in oncology research, the expansion of hospital diagnostic infrastructure, the growing adoption of imaging-based cancer detection methods, and improvements in laboratory automation.

The cancer diagnostics market size is projected for substantial expansion in the coming years. It is forecast to reach $44.69 billion in 2030, showing a compound annual growth rate (CAGR) of 11.8%. This growth during the forecast period is fueled by an increasing demand for personalized cancer therapies, the rising adoption of next-generation sequencing diagnostics, the expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, and continuous innovation in multi-cancer detection tests. Significant trends anticipated for this period encompass the increasing adoption of molecular and companion diagnostics, rising integration of AI in cancer detection, the growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, and an enhanced focus on early cancer screening.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2570&type=smp

Which Major Drivers Are Influencing The Expansion Of The Cancer Diagnostics Market?

An increase in healthcare spending is anticipated to fuel the expansion of the cancer diagnostics market moving forward. This expenditure covers the entire sum of financial resources governments, businesses, and individuals dedicate to healthcare services, encompassing medical treatments, hospital care, medications, and public health initiatives. The heightened demand for healthcare funding is primarily due to the growing prevalence of chronic diseases, which necessitate long-term and expensive treatments. Increased healthcare expenditure enhances cancer diagnostics by enabling the adoption of advanced screening technologies and broadening access to early detection services. It also improves diagnostic accuracy through greater investment in modern equipment and specialized laboratories, thereby allowing for timely intervention and better patient outcomes. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the upward trend in healthcare spending is a significant driver for the growth of the cancer diagnostics market.

Which Segments Define The Cancer Diagnostics Market Segment Structure?

The cancer diagnostics market covered in this report is segmented –

1) By Products: Companion Diagnostics, Molecular Diagnostics

2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging

3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users

Subsegments:

1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics,

2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics

Which Trends Are Shaping The Cancer Diagnostics Market?

Major companies operating within the cancer diagnostic device market are concentrating on developing technology utilizing artificial intelligence (AI), such as QAi Prostate, to achieve a competitive advantage. QAi Prostate is employed as a cancer diagnostic device for prostate cancer diagnosis. For instance, in March 2023, Qritive, a Singapore-based company developing AI-powered diagnostic tools for pathologists, launched QAi Prostate. QAi Prostate is an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. QAi Prostate employs machine learning algorithms to accurately identify and classify malignant and benign areas in prostate tissue samples. This particular tool is designed to assist pathologists in detecting prostate cancer and differentiating between malignant and benign areas in prostate tissue samples.

Who Are The Established Players Within The Cancer Diagnostics Market?

Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics

Get The Full Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Which Region Represents The Largest Share Of The Cancer Diagnostics Market?

North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=2570&type=smp

Browse Through More Reports Similar to the Global Cancer Diagnostics Market 2026, By The Business Research Company

Oncology Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795